Clinical trial
PROVIDENCE: Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With de Novo Coronary Lesions
NCT00116792 is registered in ClinicalTrials.gov with Gold, Herman K., MD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- PROVIDENCE: Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With de Novo Coronary Lesions
- Lead sponsor
- Gold, Herman K., MD
- Phase
- Phase 2/3
- Overall status
- Unknown status
- Start date
- March 31, 2004
- Completion date
- Not reported
- Enrollment
- 120 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.